Palisade Bio Inc Stock Price, News & Analysis

Palisade Bio (NASDAQ:PALI) announced breakthrough results from its Phase 1b clinical trial of PALI-2108, a first-in-class PDE4 inhibitor for ulcerative colitis treatment. The study achieved a remarkable 100% clinical response rate in all five patients with moderate-to-severe UC, demonstrating a mean 62.8% reduction in modified Mayo score.

The drug showed strong safety profile with no serious adverse events, and tissue analyses confirmed significant therapeutic effects including 40% decrease in tissue lymphocytes and 51% reduction in PDE4B expression. Phase 1a multiple ascending dose cohort data supported convenient once-daily dosing, with the active metabolite remaining detectable in colon tissue for over 36 hours.

Palisade Bio plans to complete a Phase 1b study in fibrostenotic Crohn's disease by H2 2025 and submit a Phase 2 IND application to FDA in H1 2026.

Palisade Bio (NASDAQ:PALI) has received a Notice of Allowance from the China National Intellectual Property Administration for a patent covering PALI-2108, their lead product candidate. The patent, titled "Gut Microbiota-Activated PDE4 Inhibitor Prodrug," will extend into 2045 and covers composition of matter claims.

PALI-2108 is a first-in-class PDE4 inhibitor targeting the terminal ileum and colon for treating fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC). The drug is currently being evaluated in a Phase 1b/2a clinical trial. The Chinese Inflammatory Bowel Disease market represents a significant opportunity, with forecasts approaching $1B in total revenues by 2030.

Palisade Bio (NASDAQ:PALI), a clinical-stage biopharmaceutical company, has announced an agreement with accredited investors to exercise existing warrants for 4,318,905 shares of common stock at a reduced price of $0.9047 per share, down from the original $1.40.

The transaction is expected to generate gross proceeds of approximately $3.9 million for working capital and general corporate purposes. In exchange, investors will receive new unregistered warrants (Replacement Warrants) to purchase up to 8,637,810 shares at $0.9047 per share, exercisable for five years after shareholder approval.

Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for this transaction. The company will file a registration statement with the SEC for the resale of shares issuable upon exercise of the Replacement Warrants.

Palisade Bio (NASDAQ:PALI), a clinical-stage biopharmaceutical company developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.

During the conference, CEO JD Finley shared insights about his career journey, his commitment to the company, and his enthusiasm for Palisade's development programs. The presentation is now accessible on-demand through virtualinvestorco.com and the company's investor relations website.

Palisade Bio (NASDAQ:PALI) has appointed Dr. Emil Chuang to its Board of Directors. Dr. Chuang brings nearly 25 years of pharmaceutical and clinical experience in gastroenterology, with expertise spanning from preclinical research through Phase 1-4 clinical development.

Dr. Chuang's notable achievements include contributions to two successful regulatory approvals: infliximab for pediatric Crohn's disease and lorcaserin for morbid obesity. Currently serving as Chief Medical Officer at Intrinsic Medicine, he has previously held leadership positions at Nestlé Health Science, Takeda, and Progenity. His expertise will support Palisade Bio's clinical programs in Fibrostenotic Crohn's Disease and Ulcerative Colitis, particularly focusing on the development of PALI-2108.

Palisade Bio (NASDAQ: PALI) announced positive Phase 1a results for PALI-2108, their novel terminal ileum and colon-targeted PDE4 B/D inhibitor for fibrostenotic Crohn's disease and ulcerative colitis. The study successfully met its primary endpoints, demonstrating favorable safety, tolerability, and pharmacokinetics. Key findings include: no serious adverse events across SAD/MAD cohorts, only mild reversible TEAEs at higher doses, and confirmation of the drug's targeted delivery profile. PK analysis showed therapeutically relevant concentrations in colon tissue for up to 24 hours post-dose with low systemic exposure. Based on these results, Palisade Bio plans to initiate a Phase 1b cohort in fibrostenotic Crohn's disease patients while preparing for Phase 2 clinical programs.

Palisade Bio (NASDAQ: PALI) presented positive preclinical data for PALI-2108, their colon-specific PDE4 inhibitor prodrug for treating ulcerative colitis, at Digestive Disease Week 2025. The research demonstrated that PALI-2108 effectively improved clinical parameters of colitis in a dose-dependent manner, showing significant reduction in PDE4B expression and TNF-α suppression compared to standard treatments.

The company showcased results through two posters, with one selected as a Poster of Distinction. Key findings revealed PALI-2108's favorable absorption and bioavailability, with minimal CNS toxicity. The drug is currently in a Phase 1a/b clinical trial, with topline data from the Phase 1a portion expected by the end of May 2025.

Palisade Bio (NASDAQ: PALI) has been selected to present at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit in Boston, MA from May 13-15, 2025. Dr. Joerg Heyer, Head of Translational Science and Medicine, will deliver an oral presentation titled "Improving Patient Subtyping with AI-Driven Insights to Unlock Better Insights into IBD Heterogeneity & Smash the Efficacy Ceiling" on May 13, 2025, from 9:30 AM to 10:00 AM ET.

The presentation falls under the session "Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient Outcomes." The summit aims to explore advancements in precision medicine strategies and treatment development for IBD patients.

Palisade Bio (NASDAQ: PALI) has successfully completed the Phase 1a portion of its Phase 1a/b study for PALI-2108, a treatment for Ulcerative Colitis (UC). The study included five Single Ascending Dose (SAD) cohorts, four Multiple Ascending Dose (MAD) cohorts, and food effects crossover.

Preliminary results showed promising safety data with no serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs. Several MAD cohorts (15mg-30mg BID) were completed within the expected therapeutic dose range, with minimal adverse events. Only one withdrawal occurred in the highest 50mg twice-daily dosage cohort.

The company is currently screening and dosing patients for the Phase 1b UC cohort, with one subject having completed this portion. Topline data from Phase 1a is expected by May 2025, with complete Phase 1a/b results anticipated in the first half of 2025.